Visionary Holdings Inc Dossier - Source-backed chat

Visionary Holdings Inc

GVNASDAQ

SectorConsumer Discretionary

IndustryEducation Services

Beta (adjusted)0.90

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.14Price as of 30 Jul 2026

Data confidence Sign in to view data confidence

Market Cap $785K

Shares Outstanding 5.6M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Visionary Holdings Inc. (NASDAQ: GV) is undergoing a high-risk strategic pivot from traditional education and real estate leasing to life sciences, regenerative medicine, and high-end medical aesthetics. While the company has successfully launched its stem-cell anti-aging product lines and established localized sales entities in China, its financial health is severely compromised. The company reported a massive net loss of $15.84 million on declining revenues of $5.04 million for the fiscal year ended March 31, 2025. Furthermore, severe liquidity constraints—highlighted by $54.5 million in negative working capital, bank loan defaults, and an active Nasdaq delisting determination due to reporting non-compliance—make the stock highly speculative and unsuitable for conservative investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0535%

The company fails to secure a favorable ruling from the Nasdaq Hearings Panel, leading to the formal delisting of its common shares from the Nasdaq exchange. Creditors demand immediate repayment of defaulted bank loans, forcing the company into insolvency or severe dilutive equity restructuring. The commercialization of the life sciences segment fails to gain traction.

Base CaseCentral scenario

$0.2050%

The strategic transformation into life sciences continues to progress slowly, but high operational costs and severe debt burdens limit upside. The company struggles to resolve its negative working capital position and faces prolonged regulatory hurdles with Nasdaq. While some revenue is generated from the new segments, profitability remains out of reach in the near term.

Bull CaseUpside scenario

$0.5015%

The company successfully commercializes its RAMU anti-aging and stem-cell product lines in the premium Asian regenerative medicine market. The newly established Toronto Anti-Aging and High-End Medical Aesthetics Health Care Center achieves its target of CAD 10 million in annual revenue. Debt restructuring negotiations succeed, and the company regains compliance with Nasdaq listing standards through a successful appeal process, restoring investor confidence.

Scenarios reflect our research view at the research date.

Key Investment Merits

Initial revenue contribution ($1.063 million, or 21.1% of total revenue) from the newly established life sciences and regenerative medicine segment.
Strategic partnerships established with specialized biotech firms, such as Jiangsu Yike Regenerative Medicine Technology, to co-develop global medical aesthetics markets.
Appointment of experienced leadership, including Wenxuan Cai as CEO of Visionary Health Technology Group Limited, to drive commercialization in China.

Key Investment Risks

Active Nasdaq delisting determination issued on June 4, 2026, due to failure to timely file periodic financial reports (Form 6-K).
Severe financial distress, including a net loss of $15.84 million, negative working capital of $54.5 million, and active bank loan defaults.
Material weaknesses in internal control over financial reporting (ICFR) due to a lack of in-house US GAAP and SEC reporting expertise.

Thesis Invalidation Triggers

Formal delisting of GV common shares from the Nasdaq exchange.
Inability to secure debt extensions or restructuring agreements with major creditors, leading to foreclosure or bankruptcy.
Failure of the life sciences segment to achieve meaningful sequential revenue growth in upcoming fiscal periods.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.